Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Effecty vs FitRx

Two GLP-1 desks, one scoreboard. We put Effecty and FitRx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 19 · Grade B

Effecty

Visit Effecty Full brief →
vs
No. 106 · Grade C

FitRx

Visit FitRx Full brief →

FDA warning letter, February 2026 — issued to FitRX, LLC dba FitRx. See the FDA's warning letter database.

The verdict

Effecty takes this head-to-head.

Effecty scores 86 to 72 on our six-factor Brief Score — One of the few accredited desks pairing compounded pricing with brand-name access, nationwide.

That doesn't make FitRx a bad call — it's best for readers who want insured patients seeking brand-name glp-1 access with compounded fallback. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
46
Supply Reliability
87
80
Transparency
87
88
Access Breadth
90
86
Clinical Oversight
87
76
Track Record
82
60
EffectyBrief Score 86 · 72FitRx

Price, coverage & the tracker

EffectyFitRx
Brief Score86/100 (B)72/100 (C)
Semaglutide$160/moFrom $151/mo (quarterly plan, compounded)
Tirzepatide$240/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Effecty: $160 sema / $240 tirz; LegitScript-certified with brand-name access nationwide.

FitRx: New to the tracker on 1 August 2026. The published line reads From $151/mo (quarterly plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.